669 |
Definitely: The Data Are Strong |
Matthew Price |
Jul. 21. 09 |
668 |
Interventionalist Perspective: The Treatment Pathway Was Shifted ! |
Eberhard Grube |
Jul. 21. 09 |
667 |
Surgical Perspective: CABG Is A Standard for Complete Revascularization ! |
David Paul Taggart |
Jul. 21. 09 |
666 |
Beyond DES: New Technology of Local Drug Delivery |
Juan F. Granada |
Jul. 21. 09 |
665 |
New Stent Platforms |
Eberhard Grube |
Jul. 21. 09 |
664 |
I-LOVE-IT: A Prospective, Multicenter Clinical Trial of TIVOLI Bioabsorbable Polymer Based Sirolimus-Eluting vs. ENDEAVOR Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease: 8-Month Angiographic and 1-Year Clinical Follow-Up Results |
Runlin Gao |
Jul. 21. 09 |
663 |
Comparison of DES versus BMS in Real World Registries |
Gregg W. Stone |
Jul. 21. 09 |
662 |
DES Pathobiology: Insights from Assessment of Endothelial Integrity and Function |
Renu Virmani |
Jul. 21. 09 |
661 |
The Clinical Spectrum of DES Thrombosis: Multifactorial Causes, Clinical Presentations, and Recommended Treatment Strategies |
Ron Waksman |
Jul. 21. 09 |
660 |
Future DES: What¡¯s New and Innovative in Drugs, Carrier Vehicles, and Stent Platforms |
Alexandre Abizaid |
Jul. 21. 09 |